CCRM Enterprises Inc., CCRM’s for-profit venture investment arm, creates value for regenerative medicine-based technologies and cell and gene therapy companies by making early-stage investments while leveraging CCRM’s sector expertise and specialized infrastructure.

 

CCRM Enterprises invests in early-stage ventures and projects that are developing therapeutics and enabling technologies. Through an extensive network of investors, it can bring together risk capital to support these early-stage ventures as they scale-up and advance along the development pathway. By tapping into CCRM’s manufacturing infrastructure and expertise, CCRM Enterprises provides capital-efficient support to accelerate and de-risk these high potential, early-stage ventures, further enabling the development of an advanced therapies ecosystem.

By leveraging our strong investor network, and with our current and growing access to funds for regenerative medicine-based technologies and cell and gene therapy companies, we can offer start-ups the financial backing to advance their technologies toward commercialization.

Snapshot

– Areas of interest: Breakthrough gene-editing technologies, gene-modified cell therapies, and delivery vehicles in pre-clinical proof of concept stage

– Investment range: Pre-seed to seed
– Location and indication: Agnostic

 

Offering for companies

By leveraging its strong investor and key opinion leader network, internal access to cell and gene therapy experts, and with its current and growing access to investment vehicles for regenerative medicine and cell and gene therapy companies, CCRM Enterprises catalyzes the growth of start-ups during the early stages of commercialization.

CCRM Enterprises also has in-house specialized scientific, intellectual property (IP), market intelligence and manufacturing feedback and access to support its development plans.

Working with start-ups

CCRM Enterprises works with start-ups to ensure they have the right expertise, facilities and funding to advance their therapeutic programs.

The core components of our offering to start-ups are:

Development and manufacturing infrastructure, including a 10,000 sq. ft. process development facility, and a 20,000 sq. ft. GMP facility with cell and viral vector clean rooms

Scientific expertise of nearly 60 PhDs specializing in gene editing, cell manufacturing, process optimization, viral manufacturing, iPSC differentiation and process scale-up

Advice from an expert committee composed of scientists, serial entrepreneurs and venture capitalists

Connection to global network and participation in exclusive events; information on government-supported funding programs and collaborations

A unique approach as compared to traditional venture capital (VC) groups

Offering for investors

CCRM Enterprises works with other investors and accelerator groups through direct co-investment in its incubating ventures and through the creation of investment vehicles.

CCRM Enterprises can also provide investors with the access to local/global emerging companies or opportunities coming from CCRM’s international hubs; access to an in-house specialized scientific team, IP and manufacturing teams to inform diligence; and, the potential for engagement with CCRM’s incubating ventures.

Existing investments:

– Universal T-cell
– Bone tissue regeneration
– Solutions for HSCT
– 3D tissue printing
– Retinal regeneration

– Multi-specific antibody and antibody discovery platform
– Cell-based drug delivery
– Cell therapy for liver failure
– Transfection platform